| Bioactivity | Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC50 value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation[1]. |
| Name | Anti-osteoporosis agent-4 |
| Formula | C26H26ClN3O7S |
| Molar Mass | 560.02 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen Z, et al. Synthesis and evaluation of 2-NMPA derivatives as potential agents for prevention of osteoporosis in vitro and in vivo. Eur J Med Chem. 2023 Aug 28;260:115767. |
Anti-osteoporosis agent-4
CAS: F: C26H26ClN3O7S W: 560.02
Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 atte
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.